Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × beta-D-glucosylisophosphoramide mustard × Clear all
NCT00442598 2015-03-10

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Eleison Pharmaceuticals LLC.

Phase 2 Terminated
17 enrolled 9 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡